Grace Therapeutics: 10% owner Opaleye Management bought 60,490 shares

What happened Opaleye Management Inc., identified as a 10% owner, purchased a total of 60,490 shares of Grace Therapeutics in three open-market/private purchases. The filing reports 38,796 shares at a reported weighted-average price of $2.04 on Oct 1, 2026 for $78,961; 20,000 shares at a reported weighted-average price of $2.07 on Oct 2, 2026 for $41,368; and 1,694 shares at a reported price of $2.06 on Oct 5, 2026 for $3,490. Total reported value of the purchases is $123,819.

Key details

• Transaction dates and prices: Oct 1, 2026 — 38,796 shares at $2.04 (F2) for $78,961; Oct 2, 2026 — 20,000 shares at $2.07 (F3) for $41,368; Oct 5, 2026 — 1,694 shares at $2.06 (F3) for $3,490. Transaction code: P = Purchase.
• Price ranges: F2 notes the Oct 1 purchases were executed at prices ranging from $2.00 to $2.04; F3 notes the Oct 2–5 purchases were executed at prices ranging from $2.03 to $2.07.
• Shares owned after the transaction: the filing excerpt provided does not state the post-transaction beneficial ownership total.
• Filing date: Form 4 filed Oct 5, 2026 reporting transactions dated Oct 1–5, 2026.
• Relevant footnotes: F1 states the shares are owned directly by Opaleye, L.P. and Opaleye Management acts as investment manager and may be deemed to beneficially own those securities; F2 and F3 explain reported prices are weighted averages and give purchase price ranges; F4 disclaims beneficial ownership except to the extent of pecuniary interest.

Why it may matter

• The filing shows open-market/private purchases by a 10% owner, not an executive or officer.
• The reported prices are weighted averages across multiple trades (see F2 and F3). A Form 4 does not show why the insider traded or why the company acted.